+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company's business strategy.
  • SWOT analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company's products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim International GmbH Key Recent Developments

  • Oct 07, 2022: Surrozen and Boehringer partner to develop therapy for retinal diseases
  • Jul 28, 2022: SEQSTER signs multi-year agreement with Boehringer Ingelheim to put the patient at the center of their clinical data
  • Jun 06, 2022: COVID-19 Patients with both type 2 diabetes and heart disease have greater risk of death
  • May 27, 2022: Boehringer Ingelheim leverages NWO.ai for additional insights into animal disease outbreaks
  • Apr 04, 2022: Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors' business structure and strategies with the publisher's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Boehringer Ingelheim International GmbH - Key Facts
  • Boehringer Ingelheim International GmbH - Key Employees
  • Boehringer Ingelheim International GmbH - Key Employee Biographies
  • Boehringer Ingelheim International GmbH - Major Products and Services
  • Boehringer Ingelheim International GmbH - History
  • Boehringer Ingelheim International GmbH - Company Statement
  • Boehringer Ingelheim International GmbH - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Boehringer Ingelheim International GmbH - Business Description
  • Business Segment: Animal Health
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Biopharmaceutical Contract Manufacturing
  • Overview
  • Performance
  • Business Segment: Human Pharmaceuticals
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Other Sales
  • Overview
  • Performance
  • Geographical Segment: Americas
  • Performance
  • Geographical Segment: Asia/Australia/Africa
  • Performance
  • Geographical Segment: Europe
  • Performance
  • R&D Overview
  • Boehringer Ingelheim International GmbH - Corporate Strategy
  • Boehringer Ingelheim International GmbH - SWOT Analysis
  • SWOT Analysis - Overview
  • Boehringer Ingelheim International GmbH - Strengths
  • Boehringer Ingelheim International GmbH - Weaknesses
  • Boehringer Ingelheim International GmbH - Opportunities
  • Boehringer Ingelheim International GmbH - Threats
  • Boehringer Ingelheim International GmbH - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Boehringer Ingelheim International GmbH, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Oct 07, 2022: Surrozen and Boehringer partner to develop therapy for retinal diseases
  • Jul 28, 2022: SEQSTER signs multi-year agreement with Boehringer Ingelheim to put the patient at the center of their clinical data
  • Jun 06, 2022: COVID-19 Patients with both type 2 diabetes and heart disease have greater risk of death
  • May 27, 2022: Boehringer Ingelheim leverages NWO.ai for additional insights into animal disease outbreaks
  • Apr 04, 2022: Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
  • Mar 01, 2022: BioMed X Institute and Boehringer Ingelheim start new research project in brain sensor development
  • Jan 25, 2022: Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
  • Oct 27, 2021: Boehringer Ingelheim opens high-tech tablet production facility in Ingelheim
  • Oct 25, 2021: Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
  • Oct 19, 2021: Boehringer Ingelheim and partners to accelerate development of first-in-class gene therapy for patients with cystic fibrosis
Section 5 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Boehringer Ingelheim International GmbH, Key Facts
  • Boehringer Ingelheim International GmbH, Key Employees
  • Boehringer Ingelheim International GmbH, Key Employee Biographies
  • Boehringer Ingelheim International GmbH, Major Products and Services
  • Boehringer Ingelheim International GmbH, History
  • Boehringer Ingelheim International GmbH, Other Locations
  • Boehringer Ingelheim International GmbH, Subsidiaries
  • Boehringer Ingelheim International GmbH, Key Competitors
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Boehringer Ingelheim International GmbH, Recent Deals Summary
List of Figures
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer Inc
  • Eli Lilly and Co
  • AnaptysBio Inc
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Phibro Animal Health Corp
  • F. Hoffmann-La Roche Ltd
  • AnaptysBio Inc
  • Eli Lilly and Co
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Phibro Animal Health Corp
  • F. Hoffmann-La Roche Ltd